Navigation Links
NeoStem to Present at Rodman & Renshaw's 12th Annual Healthcare Conference
Date:9/13/2010

NEW YORK, Sept. 13 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Chief Executive Officer, Robin Smith, M.D., MBA, will present on the Company's latest strategic developments at Rodman & Renshaw's 12th Annual Healthcare Conference at the New York Palace Hotel in New York City on September 13-15, 2010.

Dr. Smith is scheduled to present on Monday, September 13th, from 10:25am to 10:45am in the Garrison Salon on the 5th Floor.

Leading emerging growth biotechnology companies will present at the conference, which will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities.

"I am always excited to present at this annual conference, as it is an opportunity to reach hundreds of the industry's most influential professionals as well as sophisticated investors looking to capitalize on next generation healthcare companies. It is an opportunity to share our progress over the past year as well as our pathway for future outlining milestones to track our expansion progress," said Dr. Robin Smith, CEO and Chairman of the Board of NeoStem.

About NeoStem, Inc.NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL™ Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K  filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic and other filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.NeoStem, Inc.Robin Smith, CEO Phone: +1 (212) 584-4174 E-mail: rsmith@neostem.comhttp://www.neostem.com
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
4. NeoStem Completes $500,000 Private Placement With Strategic Investor
5. NeoStems New York City Adult Stem Cell Collection Center Has Opened and Begun Collections
6. NeoStem Receives Notice of Noncompliance from NYSE Alternext US
7. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
8. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
9. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
10. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
11. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... BOSTON , Feb. 16, 2017 /PRNewswire/ ... for rare genetic deficiencies that result in ... of a $41 million mezzanine round of ... Ipsen, OrbiMed, MPM Capital, New Enterprise Associates, ... an undisclosed public healthcare investment fund. Rhythm ...
(Date:2/15/2017)... CA (PRWEB) , ... February 15, 2017 , ... ... that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with single ... completely automatizes all of the functions of setting up and taking the image once ...
(Date:2/15/2017)... , Feb. 15, 2017 Windtree ... biotechnology company focused on developing aerosolized KL4 surfactant ... has completed a $10.5 million private placement of ... it has sufficient capital to fund its operations ... trial data release in mid-2017. Windtree ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):